DB99 (Clone A) Aptamer Details
ID# 8196
Structure
Chemistry
RNA
Target
GD2
Category
Protein
Affinity (Kd)
21.21 nM
Length
66
Aptazyme
No
Sequence (3-char table code)
G
A
C
U/T
5'-dCpdCpdGpdCpdCpdCpdApdApdApdTpdCpdCpdCpdTpdApdApdGpdApdGpdCpdApdCpdApdApdApdCpdApdCpdCpdApdApdApdCpdApdCpdApdApdCpdCpdApdCpdCpdCpdCpdApdApdCpdCpdApdGpdApdCpdApdCpdApdCpdTpdApdCpdApdCpdApdCpdGpdCpdAp-3'
Molecular Weight: 66
Extinction Coefficient:
Binding Conditions / Buffer
1X PBS (pH 7.4)
Selections carried out in vivo in six- to eight-week-old female immunodeficient BALB/c mice (CAnN. Cg-Foxn1nu/Crl).
Binding Temp: 37°C
Refolding Protocol
If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Reference
Zhang, L., Wang, M., Zhu, Z., Chen, S., Wu, H., Yang, Y., Che, F., Li, Q., & Li, H. (2021). A GD2-aptamer-mediated, self-assembling nanomedicine for targeted multiple treatments in neuroblastoma theranostics. Molecular therapy. Nucleic acids, 26, 732–748. https://doi.org/10.1016/j.omtn.2021.08.021
Request a Quote
Have your aptamer oligo synthesized by Aptagen.
